Effects of β-aminoisobutyric acid on leptin production and lipid homeostasis: Mechanisms and possible relevance for the prevention of obesity

Fundamental and Clinical Pharmacology

Volumn 24, Issue 3, 2010, Pages 269-282

  Begriche, Karima ^a   Massart, Julie ^a   Fromenty, Bernard ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Amino acid; Drug; Fatty acid oxidation; Fatty liver; Leptin; Obesity

Indexed keywords

3 AMINO 2 METHYLPROPIONIC ACID; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ADIPONECTIN; CARNITINE PALMITOYLTRANSFERASE I; DIDANOSINE; FATTY ACID; FATTY ACID SYNTHASE; G PROTEIN COUPLED RECEPTOR; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; ISOBUTYRIC ACID; KETONE; LEPTIN; LIPID; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRUVATE KINASE; STAVUDINE; TRIACYLGLYCEROL; VALINE; ZALCITABINE; ZIDOVUDINE;

ANTIINFLAMMATORY ACTIVITY; BODY FAT; BODY MASS; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FATTY ACID OXIDATION; FOOD INTAKE; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; INHIBITION KINETICS; LEAN BODY WEIGHT; LIPID METABOLISM; LIPID OXIDATION; LIPOGENESIS; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; THERMOGENESIS; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

AMINOISOBUTYRIC ACIDS; ANIMALS; HOMEOSTASIS; HUMANS; LEPTIN; LIPID METABOLISM; MICE; MICE, OBESE; OBESITY;

EID: 77952566492     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00765.x     Document Type: Review

References (123)

1. Kopelman P.G. Obesity as a medical problem. Nature (2000) 404 635 643.
2. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH. Causes, consequences and possible means to prevent it. Mitochondria (2006) 6 1 38. (Pubitemid 43250588)
3. Padwal R.S., Majumbar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (2007) 369 71 77.
4. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 368 1660 1672. (Pubitemid 46048528)
5. Mitchell P.B., Morris M.J. Depression and anxiety with rimonabant. Lancet (2007) 370 1671 1672.
6. Bray G.A., Ryan D.H. Drug treatment of the overweight patient. Gastroenterology (2007) 132 2239 2252.
7. Note R., Maisonneuve C., Lettéron P., et al. Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three-dual-NRTI treatments. Antimicrob. Agents Chemother. (2003) 47 3384 3392. (Pubitemid 37345694)
8. Maisonneuve C., Igoudjil A., Begriche K., et al. Effects of zidovudine, stavudine and β-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir. Ther. (2004) 9 803 812. (Pubitemid 39434344)
9. Begriche K., Massart J., Abbey-Toby A., Igoudjil A., Lettéron P., Fromenty B. β-Aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency. Obesity (2008) 16 2053 2067.
10. Gougeon M.L., Penicaud L., Fromenty B., Leclercq P., Viard J.P., Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir. Ther. (2004) 9 161 177. (Pubitemid 38560209)
11. Igoudjil A., Begriche K., Pessayre D., Fromenty B. Mitochondrial, metabolic and genotoxic effects of antiretroviral nucleoside reverse-transcriptase inhibitors. Anti-infect. Agents Med. Chem. (2006) 5 273 292. (Pubitemid 44027706)
12. Domingo P., Vidal F., Domingo J.C., et al. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur. J. Clin. Invest. (2005) 35 771 780. (Pubitemid 41783595)
13. Viengchareun S., Caron M., Auclair M., et al. Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir. Ther. (2007) 12 919 929. (Pubitemid 47492561)
14. 14C]thymidine in mice. J. Pharmacol. Exp. Ther. (1991) 257 479 486.
15. Cretton E.M., Zhou Z., Kidd L.B., et al. In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine. Antimicrob. Agents Chemother. (1993) 37 1816 1825. (Pubitemid 23265535)
16. Bray G.A., Tartaglia L.A. Medicinal strategies in the treatment of obesity. Nature (2000) 404 672 677.
17. Ishigaki Y., Katagiri H., Yamada T., et al. Dissipating excess energy stored in the liver is a potential treatment strategy for diabetes associated with obesity. Diabetes (2005) 54 322 332.
18. Ronnett G.V., Kim E.K., Landree L.E., Tu Y. Fatty acid metabolism as a target for obesity treatment. Physiol. Behav. (2005) 85 25 35. (Pubitemid 40744974)
19. Klaus S., Pültz S., Thöne-Reineke C., Wolfram S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int. J. Obes. (2005) 29 615 623. (Pubitemid 40769483)
20. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. (1995) 67 101 154.
21. Igoudjil A., Massart J., Begriche K., Descatoire V., Robin M.A., Fromenty B. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol. In Vitro (2008) 22 887 898.
22. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature (1998) 395 763 770. (Pubitemid 28485436)
23. Camus M.C., Aubert R., Bourgeois F., Herzog J., Alexiu A., Lemonnier D. Serum lipoprotein and apolipoprotein profiles of the genetically obese ob/ob mouse. Biochim. Biophys. Acta (1988) 961 53 64.
24. Lindström P. The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorldJournal (2007) 7 666 685. (Pubitemid 46850696)
25. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 37 343 350. (Pubitemid 36152533)
26. Robin M.A., Demeilliers C., Sutton A., et al. Alcohol increases tumor necrosis factor-α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice. Hepatology (2005) 42 1280 1290. (Pubitemid 43260030)
27. Leclercq I.A., Farrell G.C., Schriemer R., Robertson G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. (2002) 37 206 213. (Pubitemid 34833082)
28. Begriche K., Igoudjil I., Abbey-Toby A., et al. A thymine catabolite, β-aminoisobutyric acid, reduces hepatic dysfunction and metabolic disorders in overweight or obese mice. J. Hepatol. (2005) 42 (Suppl) 243.
29. Begriche K., Lettéron P., Abbey-Toby A., et al. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am. J. Physiol. Endocrinol. Metab. (2008) 294 E939 E951.
30. Xiong Y., Miyamoto N., Shibata K., et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc. Natl. Acad. Sci. USA (2004) 101 1045 1050. (Pubitemid 38160581)
31. Cammisotto P.G., Bendayan M. Leptin secretion by white adipose tissue and gastric mucosa. Histol. Histopathol. (2007) 22 199 210. (Pubitemid 46117106)
32. Cammisotto P.G., Gélinas Y., Deshaies Y., Bukowiecki L.J. Regulation of leptin secretion from white adipocytes by insulin, glycolytic substrates, and amino acids. Am. J. Physiol. Endocrinol. Metab. (2005) 289 E166 E171. (Pubitemid 40874948)
33. Griffith O.W. β-Amino acids: mammalian metabolism and utility as α-amino acid analogues. Annu. Rev. Biochem. (1986) 55 855 878. (Pubitemid 16070790)
34. Cammisotto P.G., Gélinas Y., Deshaies Y., Bukowiecki L.J. Regulation of leptin secretion from white adipocytes by free fatty acids. Am. J. Physiol. Endocrinol. Metab. (2003) 289 E166 E171. (Pubitemid 37010829)
35. Trachtman H., Futterweit S., Sturman J.A. Cerebral taurine transport is increased during streptozocin-induced diabetes in rats. Diabetes (1992) 41 1130 1140.
36. Dominy J., Thinschmidt J.S., Peris J., Dawson R., Papke R.L. Taurine-induced long-lasting potentiation in the rat hippocampus shows a partial dissociation from total hippocampal taurine content and independence from activation of known taurine transporters. J. Neurochem. (2004) 89 1195 1205. (Pubitemid 38715837)
37. Takasaki M., Satsu H., Shimizu M. Physiological significance of the taurine transporter and taurine biosynthetic enzymes in 3T3-L1 adipocytes. Biofactors (2004) 21 419 421. (Pubitemid 40921897)
38. Wang Z.W., Zhou Y.T., Kakuma T., et al. Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. Proc. Natl. Acad. Sci. USA (1999) 96 10373 10378. (Pubitemid 29422565)
39. Asilmaz E., Cohen P., Miyazaki M., et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J. Clin. Invest. (2004) 113 414 424. (Pubitemid 38544185)
40. Bjorbaek C., Kahn B.B. Leptin signalling in the central nervous system and the periphery. Recent Prog. Horm. Res. (2004) 59 305 331.
41. Liang C.P., Tall A.R. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. (2001) 276 49066 49076. (Pubitemid 37370612)
42. Toyoshima Y., Gavrilova O., Yakar S., et al. Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology (2005) 146 4024 4035. (Pubitemid 41175774)
43. Cohen P., Miyasaki M., Socci N.D., et al. Role of stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science (2002) 297 240 243. (Pubitemid 34761283)
44. Biddinger S.B., Miyasaki M., Boucher J., Ntambi J.M., Kahn C.R. Leptin suppresses stearoyl-CoA desaturase-1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. Diabetes (2006) 55 2032 2041. (Pubitemid 44509977)
45. Muoio D.M., Dohm G.L. Peripheral metabolic actions of leptin. Best Pract. Res. Clin. Endocrinol. Metab. (2002) 16 653 666. (Pubitemid 36040543)
46. Wein S., Ukropec J., Gasperikova D., Klimes I., Sebökova E. Concerted action of leptin in regulation of fatty acid oxidation in skeletal muscle and liver. Exp. Clin. Endocrinol. Diabetes (2007) 115 244 251. (Pubitemid 46762252)
47. Lee Y., Yu X., Gonzales F., et al. PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc. Natl. Acad. Sci. USA (2002) 99 11848 11853. (Pubitemid 34994487)
48. Suzuki A., Okamoto S., Lee S., Saito K., Shiuchi T., Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor-α gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the α2 form of AMP-activated protein kinase. Mol. Cell. Biol. (2007) 27 4317 4327. (Pubitemid 46906556)
49. Ajuwon K.M., Kuske J.L., Anderson D.B., et al. Chronic leptin administration increases serum NEFA in the pig and differentially regulates PPAR expression in adipose tissue. J. Nutr. Biochem. (2003) 14 576 583.
50. Huang W., Dedousis N., Bandi A., Lopaschuk G.D., O'Doherty R.M. Liver triglyceride secretion and lipid oxidative metabolism are rapidly altered by leptin in vivo. Endocrinology (2006) 147 1480 1487. (Pubitemid 43244383)
51. Huang W., Dedousis N., Bhatt B.A., O'Doherty R.M. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. J. Biol. Chem. (2004) 279 21695 21700. (Pubitemid 38679354)
52. Andreelli F., Foretz M., Knauf C., et al. Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology (2006) 147 2432 2441.
53. Steinberg G.R., McAinch A.J., Chen M.B., et al. The suppressor of cytokine signalling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J. Clin. Endocrinol. Metab. (2006) 91 3592 3597.
54. Ntambi J.M., Miyazaki M., Stoehr J.P., et al. Loss of stearoyl-CoA desaturase function protects mice against adiposity. Proc. Natl. Acad. Sci. USA (2002) 99 11482 11486. (Pubitemid 34920951)
55. Sampath H., Ntambi J.M. Stearoyl-coenzyme A desaturase 1, sterol regulatory element binding protein 1c and peroxisome proliferator-activated receptor-α: independent and interactive roles in the regulation of lipid metabolism. Curr. Opin. Clin. Nutr. Metab. Care (2006) 9 84 88. (Pubitemid 44090029)
56. Friedman J.M. Obesity in the new millennium. Nature (2000) 404 632 634.
57. Dhillon H., Kalra S.P., Kalra P.S. Dose-dependent effects of central leptin gene therapy on genes that regulate body weight and appetite in the hypothalamus. Mol. Ther. (2001) 4 139 145. (Pubitemid 32776505)
58. Ukropec J., Anunciado R.V., Ravussin Y., Kozak L.P. Leptin is required for uncoupling protein-1 independent thermogenesis during cold stress. Endocrinology (2006) 147 2468 2480.
59. Cohen S.E., Kokkotou E., Biddinger S.B., et al. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knockout (LIRKO) mice. J. Biol. Chem. (2007) 282 23672 23678. (Pubitemid 47311938)
60. Szanto I., Kahn C.R. Selective interaction between leptin and insulin signalling pathways in a hepatic cell line. Proc. Natl. Acad. Sci. USA (2000) 97 2355 2360. (Pubitemid 30134073)
61. Briscoe C.P., Hanif S., Arch J.R., Tadayyon M. Leptin receptor long-form signalling in a human liver cell line. Cytokine (2001) 14 225 229. (Pubitemid 32619903)
62. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., Diehl A.M. Metformin reverses fatty liver disease in obese leptin-deficient mice. Nat. Med. (2000) 6 998 1003.
63. Licinio J., Caglayan S., Ozata M., et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc. Natl. Acad. Sci. USA (2004) 101 4531 4536. (Pubitemid 38437445)
64. Farooqi I.S., Keogh J.M., Kamath S., et al. Partial leptin deficiency and human adiposity. Nature (2001) 414 34 35.
65. Hager J., Clément K., Francke S., et al. A polymorphism in the 5' untranslated region of the human ob gene is associated with low leptin levels. Int. J. Obes. Relat. Metab. Disord. (1998) 22 200 205. (Pubitemid 28112018)
66. Ravussin E., Pratley R.E., Maffei M., et al. Relatively low plasma leptin concentrations precede weight gain in Pima Indians. Nat. Med. (1997) 3 238 240. (Pubitemid 27064713)
67. Chung W.K., Belfi K., Chua M., et al. Heterozygosity for Lep(ob) or Lep(rdb) affects body composition and leptin homeostasis in adult mice. Am. J. Physiol. (1998) 274 R985 R990. (Pubitemid 28217749)
68. German A.J. The growing problem of obesity in dogs and cats. J. Nutr. (2006) 136 1940S 1946S. (Pubitemid 43973603)
69. Appleton D.J., Rand J.S., Sunvold G.D. Plasma leptin concentrations in cats: reference range, effect of weight gain and relationship with adiposity as measured by dual energy X-ray absorptiometry. J. Feline Med. Surg. (2000) 2 191 199.
70. Ishioka K., Soliman M.M., Sagawa M., et al. Experimental and clinical studies on plasma leptin in obese dogs. J. Vet. Med. Sci. (2002) 64 349 353. (Pubitemid 135746730)
71. Shibata H., Sasaki N., Honjoh T., et al. Feline leptin: immunogenic and biological activities of the recombinant protein, and its measurement by ELISA. J. Vet. Med. Sci. (2003) 65 1207 1211. (Pubitemid 41380045)
72. Schmieden V., Betz H. Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Mol. Pharmacol. (1995) 48 919 927.
73. Ikejima K., Iimuro Y., Forman D.T., Thurman R.G. A diet containing glycine improves survival in endotoxin shock in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. (1996) 271 G97 G103. (Pubitemid 26299731)
74. Froh M., Thurman R.G., Wheeler M.D. Molecular evidence for a glycine-gated chloride channel in macrophages and leukocytes. Am. J. Physiol. Gastrointest. Liver Physiol. (2002) 283 G856 G863. (Pubitemid 35033928)
75. van Kuilenburg A.B., Meinsma R., Beke E., et al. β-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum. Mol. Genet. (2004) 13 2793 2801. (Pubitemid 39562543)
76. van Kuilenburg A.B., Stroomer A.E., Abeling N.G., van Gennip A.H. A pivotal role for β-aminoisobutyric acid and oxidative stress in dihydropyrimidine dehydrogenase deficiency? Nucleosides Nucleotides Nucleic Acids (2006) 25 1103 1106.
77. Birdsall T.C. Therapeutic applications of taurine. Alt. Med. Rev. (1998) 3 128 136.
78. Sinha M., Manna P., Sil P.C. Taurine, a conditionally essential amino acid, ameliorates arsenic-induced cytotoxicity in murine hepatocytes. Toxicol. In Vitro (2007) 21 1419 1428. (Pubitemid 350103535)
79. Farroqi I.S., O'Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am. J. Clin. Nutr. (2009) 89 980S 984S.
80. Fried S.K., Ricci M.R., Russell C.D., Laferrère B. Regulation of leptin production in humans. J. Nutr. (2000) 130 3127S 3131S. (Pubitemid 32005354)
81. Rance K.A., Johnstone A.M., Murison S., Duncan J.S., Wood S.G., Speakman J.R. Plasma leptin levels are related to body composition, sex, insulin levels and the A55V polymorphism of the UCP2 gene. Int. J. Obes. (2007) 31 1311 1318. (Pubitemid 47172610)
82. Shimizu H., Tsuchiya T., Sato N., Shimomura Y., Kobayashi I., Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care (1998) 21 1470 1474. (Pubitemid 28405198)
83. Hägg S., Söderberg S., Ahrén B., Olsson T., Mjörndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J. Clin. Psychiatry (2001) 62 843 848. (Pubitemid 33131169)
84. Ihara S., Shimamoto K., Watanabe H., Sakai R., Kawana M. An α1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. Hypertens. Res. (2006) 29 805 811. (Pubitemid 44842816)
85. Boberg J., Metzdorff S., Wortziger R., et al. Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats. Toxicology (2008) 250 75 81.
86. Ong K.K., Ahmed M.L., Sherriff A., et al. Cord blood leptin is associated with size at birth and predicts infancy weight gain in humans. J. Clin. Endocrinol. Metab. (1999) 84 1145 1148. (Pubitemid 29138257)
87. Fonseca V.M., Sichieri R., Moreira M.E., Moura A.S. Early postnatal growth in preterm infants and cord blood leptin. J. Perinatol. (2004) 24 751 756. (Pubitemid 39618581)
88. Mantzoros C.S., Rifas-Shiman S.L., Williams C.J., Fargnoli J.L., Kelesidis T., Gillman M.W. Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a prospective cohort study. Pediatrics (2009) 123 682 689.
89. Yu I.C., Lin H.Y., Liu N.C., et al. Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology (2008) 149 2361 2368.
90. Pico C., Oliver P., Sanchez J., et al. The intake of physiological doses of leptin during lactation in rats prevents obesity in later life. Int. J. Obes. (2007) 31 1199 1209. (Pubitemid 47172621)
91. Sanchez J., Priego T., Palou M., Tobaruela A., Palou A., Pico C. Oral supplementation with physiological doses of leptin during lactation in rats improves insulin sensitivity and affects food preferences later in life. Endocrinology (2008) 149 733 740. (Pubitemid 351159328)
92. Palou A., Pico C. Leptin intake during lactation prevents obesity and affects food intake and food preferences in later life. Appetite (2009) 52 249 252.
93. Cammisotto P.G., Gingras D., Bendayan M. Transcytosis of gastric leptin through the rat duodenal mucosa. Am. J. Physiol. Gastrointest. Liver Physiol. (2007) 293 G773 G779. (Pubitemid 47605926)
94. Canals I., Carmona M.C., Amigo M., et al. A functional leptin system is essential for sodium tungstate antiobesity action. Endocrinology (2009) 150 642 650.
95. Bjorbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., Flier J.S. Identification of SOCS-3 as a potential mediator o central leptin resistance. Mol. Cell (1998) 1 619 625. (Pubitemid 128374698)
96. Enriori P.J., Evans A.E., Sinnayah P., et al. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab. (2007) 5 181 194. (Pubitemid 46317303)
97. Vila L., Roglans N., Alegret M., Sanchez R.M., Vazquez-Carrera M., Laguna J.C. Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology (2008) 48 1506 1516.
98. Roth J.D., Roland B.L., Cole R.L., et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity. Evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA (2008) 105 7257 7262.
99. Trevaskis J.L., Coffey T., Cole R., et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology (2008) 149 5679 5687.
100. Gejyo F., Kinoshita Y., Ikenaka T. Elevation of serum levels of β-aminoisobutyric acid in uremic patients and the toxicity of the amino acid. Clin. Nephrol. (1987) 8 520 525.
101. Igoudjil A., Abbey-Toby A., Begriche K., et al. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir. Ther. (2007) 12 389 400. (Pubitemid 46787984)
102. Löfgren P., Andersson I., Adolfsson B., et al. Long-term prospective and controlled studies demonstrate adipose tissue hypercellularity and relative leptin deficiency in the postobese state. J. Clin. Endocrinol. Metab. (2005) 90 6207 6213. (Pubitemid 41606545)
103. Rosenbaum M., Goldsmith R., Bloomfield D., et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. (2005) 115 3579 3586. (Pubitemid 43121846)
104. Ahima R.S. Revisiting leptin's role in obesity and weight loss. J. Clin. Invest. (2008) 118 2380 2383.
105. Hulver M.W., Berggren J.R., Cortright R.N., et al. Skeletal muscle lipid metabolism with obesity. Am. J. Physiol. Endocrinol. Metab. (2003) 284 E741 E747.
106. Houmard J.A. Intramuscular lipid oxidation and obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008) 294 R1111 R1116.
107. Friedman M.I. Obesity and the hepatic control of feeding behavior. Drug News Perspect. (2007) 20 573 578.
108. Ji H., Friedman M.I. Reduced capacity for fatty acid oxidation in rats with inherited susceptibility to diet-induced obesity. Metabolism (2007) 56 1124 1130. (Pubitemid 47021179)
109. Bansode R.R., Huang W., Roy S.K., Mehta M., Mehta K.D. Protein kinase Cβ deficiency increases fatty acid oxidation and reduces fat storage. J. Biol. Chem. (2008) 283 231 236.
110. Ruderman N., Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat. Rev. Drug Discov. (2004) 3 340 351. (Pubitemid 38499761)
111. Watt M.J., Steinberg G.R., Chen Z.P., Kemp B.E., Febbraio M.A. Fatty acids stimulate AMP-activated protein kinase and enhance fatty acid oxidation in L6 myotubes. J. Physiol. (2006) 574 139 147.
112. Choi C.S., Savage D.B., Abu-Elheiga L., et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc. Natl. Acad. Sci. USA (2007) 104 16480 16485. (Pubitemid 350211044)
113. Waring J.F., Yang Y., Healan-Greenberg C.H., et al. Gene expression analysis in rats treated with experimental acetyl-coenzyme A carboxylase inhibitors suggests interactions with the peroxisome proliferator-activated receptor-α pathway. J. Pharmacol. Exp. Ther. (2008) 324 507 516. (Pubitemid 351185841)
114. Covington D.K., Briscoe C.A., Brown A.J., Jayawickreme C.K. The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. Biochem. Soc. Trans. (2006) 34 770 773.
115. Taggart A.K., Kero J., Gan X., et al. (D)-β-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. (2005) 280 26649 26652. (Pubitemid 41040696)
116. Ge H., Weiszmann J., Reagan J.D., et al. Elucidation of signalling and functional activities of an orphan GPCR-GPR81. J. Lipid Res. (2008) 49 797 803.
117. Xue C., Bahn Y.S., Cox G.M., Heitman J. G protein-coupled receptor Gpr4 senses amino acids and activates the cAMP-PKA pathway in Cryptococcus neoformans. Mol. Biol. Cell (2006) 17 667 679. (Pubitemid 43191102)
118. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 125 437 443. (Pubitemid 36929425)
119. Galle P.R., Krammer P.H. CD95-induced apoptosis in human liver disease. Semin. Liver Dis. (1998) 18 141 151. (Pubitemid 28224005)
120. Jiang S., Song M.J., Shin E.C., Lee M.O., Kim S.J., Park J.H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology (1999) 29 101 110. (Pubitemid 29023992)
121. Pinkoski M.J., Brunner T., Green D.R., Lin T. Fas and Fas ligand in gut and liver. Am. J. Physiol. Gastroenterol. Liver Physiol. (2000) 278 G354 G366. (Pubitemid 30152480)
122. Myers M.G., Cowley M.A., Münzberg H. Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol. (2008) 70 537 556. (Pubitemid 351738191)
123. Steinberg G.R., Parolin M.L., Heigenhauser G.J., Dyck D.J. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am. J. Physiol. Endocrinol. Metab. (2002) 283 E187 E192.